A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Change From Baseline in log10 HIV-1 RNA Viral Load (<50/200 Copies/mL) at Weeks 2, 4, 8, 12, 24, 36, and 48

Change from baseline in log10 HIV-1 RNA viral load (\<50/200 copies/mL) at Weeks 2, 4, 8, 12, 24, 36, and 48 were reported.

Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 36, and 48

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24

Percentage of participants with HIV-1 RNA \< 50 copies/mL were reported.

Time frame: Week 24

Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 12, 24 and 48

The immunologic change was determined by changes in Cluster of CD4+ cell count. Change from baseline in CD4+ cell count at Weeks 12, 24 and 48 were assessed.

Time frame: Baseline, Weeks 12, 24 and 48

Number of Participants That Required Discontinuation After Enrollment Based on Safety Stopping Rules

Number of participants that required discontinuation after enrollment based on safety stopping rules were reported. Stopping rules include the following reasons: a). Estimated glomerular filtration rate (eGFR) according to the Modification of Diet in Renal Disease (MDRD) formula \< 50 milliliter per minute (mL/min) b). Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to (\>=) 2.5\*upper limit of normal (ULN); c). Serum lipase \>=1.5\*ULN; d). Positive serum human chorionic gonadotropin pregnancy test (beta-hCG) for women of childbearing potential; e). Laboratory results that the investigator believes should result in discontinuation of study medication; f). Participants identified with active hepatitis C virus (HCV) infection that in the opinion of the investigator requires HCV treatment immediately or expected to be needed during the course of the study with agents not compatible with D/C/F/TAF FDC.

Time frame: Up to Week 48

Percentage of Participants Discontinuing Therapy Due to Adverse Events (AEs)

Percentage of participants discontinuing therapy due to AEs were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame: Up to Week 48

Percentage of Participants Experiencing Grade 3 and 4 Adverse Events

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.

Time frame: Up to Week 48

Percentage of Participants Experiencing Grade 3 and 4 Laboratory Abnormalities

Percentage of participants experiencing grade 3 and 4 laboratory abnormalities was assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Event (AE) Grading Table. Abnormal laboratory values with Grade 3 or higher (3=Severe; 4=potentially life-threatening) signifies an interruption of usual daily activity, requiring systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable.

Time frame: Up to Week 48

Percentage of Participants Meeting Resistance Stopping Rules, Requiring Discontinuation of Study Treatment Due to Baseline Resistance Findings

Percentage of participants meeting resistance stopping rules, requiring discontinuation of study treatment due to baseline resistance findings were reported. Investigator reviewed antiretroviral screening/baseline resistance data at Week 4, depending on availability of screening/baseline HIV genotypic drug resistance testing results from central laboratory. Participants who do not show full sensitivity to all drugs in the fixed-dose combination (FDC) study regimen according to the susceptibility assessment in the Genosure Prime report will be contacted to return to study site for early study treatment discontinuation (ESTD). Participants with identified resistance to lamivudine/Emtricitabine, attributed to the presence of the M184I/V mutation alone will be permitted to remain in the study.

Time frame: Up to Day 35

Percentage of Participants With Baseline Protease (PI), Reverse Transcriptase (RT) and Integrase (INI)-Resistance-associated Mutation (RAMs)

Percentage of Participants with resistance-associated mutations present at baseline were reported and included mutations in the domain of PR, RT (including nucleoside reverse transcriptase inhibitor \[NRTIs\] and non-nucleoside/nucleotide reverse transcriptase inhibitor \[NNRTIs\]), INI, RAMs as determined by the GenoSure Prime assay. Genotypes were not available for 7 participants due to failed amplification of viral deoxyribo nucleic acid (DNA) (that is, low viral load (VL) \[\<500 copies/mL\], reduced viral fitness, compromised sample collection/handling, primer incompatibility).

Time frame: Baseline (Day 1)

Percentage of Participants With Protocol-defined Virologic Failure (PDVF) at Week 24 and 48

Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA \<1 log10 reduction from baseline, and HIV-1 RNA \>= 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA \<50 copies/mL, a rebound in HIV 1 RNA to \>= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a \>1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result.

Time frame: Week 24 and 48

Percentage of Participants Developing Resistance-associated Mutation (RAMs) and Loss of Phenotypic Susceptibility, Upon Meeting Protocol-defined Virologic Failure (PDVF)

Percentage of participants developing RAMs and loss of phenotypic susceptibility, upon meeting PDVF were reported. Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA \<1 log10 reduction from baseline, and HIV-1 RNA greater than or equal to (\>=) 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA \<50 copies/mL, a rebound in HIV 1 RNA to \>= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a \>1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result.

Time frame: Up to Week 48

Percentage of Participants Lost-to-Follow-up Throughout the 48 Weeks of Treatment

Percentage of participants lost-to-follow-up throughout the 48 Weeks of treatment were reported.

Time frame: Up to Week 48

Percentage of Participants With Retention in Care Completed and With Documented Clinical Visit

Percentage of participants with retention in care completed and with documented clinical visit (within 90 days of discontinuation) were reported.

Time frame: Up to Week 48

Percentage of Participants With Treatment Adherence >95% Based on Pill Count at Weeks 4, 8, 12, 24, 36, and 48

Percentage of participants with treatment adherence \>95% based on pill count at Weeks 4, 8, 12, 24, 36, and 48 were reported. Treatment adherence was defined as having a treatment adherence of greater than (\>) 95 percent (%) by pill count.

Time frame: Weeks 4, 8, 12, 24, 36, and 48

Percentage of Participants With 100% Treatment Adherence Based on Participants Self-Report, Using a 4-Day Recall at Weeks 4, 8, 12, 24, 36, and 48

Percentage of participants with 100 % adherence based on participants self-report, using a 4-Day recall at Weeks 4, 8, 12, 24, 36, and 48 was reported.

Time frame: Weeks 4, 8, 12, 24, 36, and 48

Mean Total Scores for the HIV-Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4, 24, and 48

The HIV treatment satisfaction questionnaire (HIVTSQ) is based on a 10-item self-reported scale that measures overall satisfaction with treatment. The HIVTSQ items are summed up to produce a treatment satisfaction score (0 to 60) and an individual satisfaction rating for each item (0 to 6). The higher the score, the greater the treatment satisfaction.

Time frame: Weeks 4, 24, and 48

Number of Participants With Hospitalizations

Number of participants with hospitalizations (overnight) was reported.

Time frame: Up to Week 48

Duration of Hospitalizations

Duration of hospitalizations in days was reported for those participants hospitalized during the course of the study. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this OM.

Time frame: Up to Week 48

Number of Participants With Outpatient Visits

Number of participants with outpatient visits (in addition to study visits, including General practitioner visit, Specialist visit, Nurse practitioner visit, Physician assistant visit, Home healthcare nurse visit and Other visit) was reported.

Time frame: Up to Week 48

Number of Participants With Emergency Room Visits

Number of participants with emergency room visits was reported.

Time frame: Up to Week 48

Median Medical Costs of Care ((United States of America [USA] Dollars) Based on Healthcare Resource Utilization [HRU])

Median medical costs of care (United States of America \[USA\] dollars) based on healthcare resource utilization \[HRU\]) were reported. The cost of care specified for overnight hospitalization, hospital day care ward (without overnight), emergency room visit, general practitioner visit, specialist visit, nurse practitioner visit, physician assistant visit and Other visit.

Time frame: Up to Week 48

Percentage of Participants Discontinuing Therapy Due to Adverse Events (AEs) Through Week 96

Percentage of participants discontinuing therapy due to AEs were reported. An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame: Up to Week 96

Percentage of Participants Experiencing Grade 3 and 4 Adverse Events Through Week 96

AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Events with Grade 3 or higher (3=Severe; 4=life-threatening; 5=fatal) are events that significantly interrupt usual daily activity, require systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable events.

Time frame: Up to Week 96

Percentage of Participants Experiencing Grade 3 and 4 Laboratory Abnormalities Through Week 96

Percentage of participants experiencing grade 3 and 4 laboratory abnormalities were assessed by Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Event (AE) Grading Table. Abnormal laboratory values with Grade 3 or higher (3=Severe; 4=potentially life-threatening) signifies an interruption of usual daily activity, requiring systemic drug therapy/other treatment and are, in many situations, considered unacceptable or intolerable.

Time frame: Up to Week 96

Percentage of Participants With Protocol-defined Virologic Failure (PDVF) at Week 72 and 96

Virologic failure is defined as: a) Virologic Nonresponse: HIV-1 RNA \<1 log10 reduction from baseline, and HIV-1 RNA \>= 400 copies/mL at the Week 12 visit, subsequently confirmed at an unscheduled visit conducted within 2 to 4 weeks after Week 12. b) Virologic Rebound: At any visit, after achieving confirmed consecutive HIV-1 RNA \<50 copies/mL, a rebound in HIV 1 RNA to \>= 50 copies/mL, which is subsequently confirmed at a scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result; or At any visit, a \>1 log10 increase in HIV-1 RNA from the nadir, which is subsequently confirmed at the following scheduled or unscheduled visit conducted within 2 to 4 weeks of the HIV-1 RNA result.

Time frame: Weeks 72 and 96